Department of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Department of Computational Diagnostic Radiology and Preventive Medicine, The University of Tokyo Hospital, Tokyo, Japan.
ESC Heart Fail. 2022 Aug;9(4):2728-2731. doi: 10.1002/ehf2.13945. Epub 2022 Apr 16.
Pulmonary arterial hypertension (PAH) is a progressively life-threatening disease that causes right heart failure (RHF). Renal dysfunction frequently complicates PAH with RHF and is associated with a worse prognosis. Renal replacement therapy (RRT) may be a therapeutic option, although its efficacy and safety are unclear. We describe a 30-year-old male with severe PAH who developed renal insufficiency and diuretic-refractory volume overload complicated with RHF but was successfully managed with intermittent RRT via a subcutaneously fixed superficial artery for 4 years. RRT led to haemodynamic stability, which enabled us to carefully de-titrate parenteral PAH drugs without worsening RHF. This case highlights that RRT may be a potential alternative for haemodynamic and volume control of refractory fluid retention complicated with RHF in severe PAH cases. Further studies are warranted to gain more insight into patient selection and the optimal timing of RRT in PAH patients with deteriorating RHF.
肺动脉高压(PAH)是一种进行性危及生命的疾病,可导致右心衰竭(RHF)。肾功能障碍常使 PAH 合并 RHF 复杂化,并与预后较差相关。肾脏替代疗法(RRT)可能是一种治疗选择,尽管其疗效和安全性尚不清楚。我们描述了一名 30 岁男性,患有严重的 PAH,出现肾功能不全和利尿剂难治性容量超负荷合并 RHF,但通过皮下固定的浅表动脉间歇性 RRT 成功治疗 4 年。RRT 导致血流动力学稳定,使我们能够在不加重 RHF 的情况下小心地减少静脉注射 PAH 药物的剂量。该病例强调,RRT 可能是严重 PAH 合并 RHF 时难治性液体潴留导致血流动力学和容量控制的潜在替代方法。需要进一步的研究来更深入地了解选择患者和 RRT 的最佳时机,以改善 RHF 恶化的 PAH 患者的预后。